Castle Biosciences CSTL Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 77.9%-1.5pp | 79.4%-0.6pp | 79.9%-1.1pp | 81%-0.9pp | 81.9%+0.1pp | |
| Operating margin | -9.8%+2.6pp | -12.4%-2.3pp | -10.2%-3.5pp | -6.7%-2.7pp | -4%-6.6pp | |
| Net margin | -3.8%+3.2pp | -7%-3.5pp | -3.6%-0.8pp | -2.7%-1.3pp | -1.5%-7.0pp | |
| Returns | ||||||
| Return on equity | -2.8%+2.4pp | -5.2%-2.5pp | -2.7%-0.5pp | -2.2%-1.0pp | -1.2%-5.5pp | |
| Return on invested capital | -8.2%+3.1pp | -11.4%-2.5pp | -8.8%-2.9pp | -6%-2.1pp | -3.8%-6.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.7×-0.1× | 0.7×0.0× | |
| Liquidity | ||||||
| Current ratio | 6.7×+1.5× | 5.3×-1.2× | 6.5×-0.4× | 6.9×-2.5× | 9.4×+2.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $15.44-5.0% | $16.24+1.1% | $16.06+4.2% | $15.41+0.1% | $15.39-1.2% | |
| Valuation | ||||||
| Market capitalization | $694.86M+29.9% | $1.14B+71.9% | $660.52M+19.4% | $553.19M-3.1% | $570.85M-23.5% | |
| Price / sales | 2×+0.5× | 3.3×+1.4× | 1.9×+0.3× | 1.6×0.0× | 1.6×-0.6× | |
| Price / book | 1.5×+0.3× | 2.4×+1.0× | 1.4×+0.2× | 1.2×-0.1× | 1.3×-0.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Castle Biosciences's profit margins?
- Castle Biosciences (CSTL) runs a 77.9% gross margin and a -9.8% operating margin, with a -3.8% net margin.
- Where do Castle Biosciences's ratios come from?
- Every ratio is computed from Castle Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
